Advertisement

Topics

Hansa Medical begins IdeS dosing in Phase II trial for anti-GBM antibody disease

19:00 EDT 20 Jun 2017 | Net Resources International

Swedish biopharmaceutical firm Hansa Medical has begun dosing patients in its Phase II clinical trial of drug candidate IgG degrading enzyme of Streptococcus pyogenes (IdeS), to treat patients with severe anti-GBM antibody disease / Goodpasture’s dis…

Original Article: Hansa Medical begins IdeS dosing in Phase II trial for anti-GBM antibody disease

NEXT ARTICLE

More From BioPortfolio on "Hansa Medical begins IdeS dosing in Phase II trial for anti-GBM antibody disease"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...